The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the implementation of new measures to strengthen safety in the use of antidepressants. The changes will affect the information materials that patients receive when prescribed these medications. The decision resulted from a comprehensive review that involved not only independent medical experts but also patients themselves and their families. This approach made it possible to take into account the real experiences of people who have used antidepressants and to identify aspects requiring more detailed or clearer explanation. The updated materials are designed to give patients a more complete understanding of the possible effects of treatment, risks, and specific aspects of medication use. It is expected that this will help increase patient awareness and improve the interaction between doctors and those taking antidepressants, especially at the initial stages of treatment or when discontinuing it. The initiative reflects a broader trend in UK healthcare aimed at increasing transparency of medical information and strengthening the patient's role in making decisions about their own treatment. MHRA emphasises that updating information materials is part of ongoing work to monitor the safety of medicines already in circulation.